From this trial, it cannot be concluded that one particular oral form is superior to the rest
Research on GLP-1 medications and inflammatory bowel conditions remains limited, but emerging data suggests that semaglutide may actually reduce systemic inflammation markers in some patients through its effects on immune-related receptors throughout the gut
This is said to occur in a small percentage of peptide therapy patients and tends to be mild, as well as transient
There are a lot of factors that make it very hard to do a good study on these peptides. For one, such research is costly, and the wide availability of unproven peptides makes them less attractive to pursue from a financial standpoint, he says
Liver fibrosis positive area reduced compared to the Vehicle group (Figure 8D)
Many patients do regain weight after they stop taking Ozempic